EARLY MORTALITY IN LANGERHANS CELL HISTIOCYTOSIS III (LCH-III) TRIAL SUGGESTS SOME PATIENTS REQUIRE MORE EFFECTIVE THERAPY EVEN BEFORE THE 1ST RESPONSE ASSESSMENT POINT AT 6 WEEKS

PEDIATRIC BLOOD & CANCER(2020)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要